Gan & Lee Pharma’s GZR18 achieves as much as 17.23% weight loss

Beijing, China-based Gan & Lee Pharmaceuticals (SSE: 603087) announced that its independently developed long-acting GLP-1 receptor agonist (GLP-1 RA), GZR18 injection, has achieved positive results in a clinical trial for adults with obesity/overweight in China.

The Phase IIb clinical trial (CTR20231695) is a multicenter, randomized, double-blind, placebo-controlled study conducted at 25 clinical trial centers in China, recruiting a total of 340 participants.

After 30 weeks of treatment, compared to the placebo group, participants receiving different doses and frequencies of GZR18 injection (12mg, 18mg, 24mg, and 48mg Q2W; 24mg QW) had a significant reduction in the percent change in body weight from baseline.